DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Want to cut your energy bills? Here’s how five experts are doing it 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SALT LAKE CITY, May 30, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 10:00 a.m. PDT on June 13, 2017, at the Terranea Resort in Rancho Palos Verdes, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
